Therapeutic androgen receptor ligands.
In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged. This concept has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene. The discovery of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators, or SARMs).
Allan
George F
GF
Johnson and Johnson Pharmaceutical Research and Development, Department of Reproductive Therapeutics, Raritan, NJ 08869, USA.
Sui
Zhihua
Z